Università degli Studi di Firenze SST Regione Toscana

5 - Pubblicazioni
 
Pubblicazioni ultimi 4 anni

  1. Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, Maccari C, Ramundo F, Jadoon Y, Gesullo F, Ceglie S, Paoli C, Pardanani A, DeStefano V, Tefferi A, Vannucchi AM. Clinical and molecular predictors of1,607 patients. Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26332. Epub ahead ofprint. PMID: 34424575.
  2. Attardi E, Pilerci S, Attucci I, Buzzichelli A, Messeri M, Staderini M,Vannucchi AM, Antonioli E. Ninety-Minute Daratumumab Infusions for Relapsed andRefractory Multiple Myeloma: Two Years of Italian Single-Center ObservationalStudy. Clin Lymphoma Myeloma Leuk. 2021 Jun 28:S2152-2650(21)00247-0. doi:10.1016/j.clml.2021.06.018. Epub ahead of print. PMID: 34344639.
  3. Guglielmelli P, Mazzoni A, Maggi L, Kiros ST, Zammarchi L, Pilerci S, RoccaA, Spinicci M, Borella M, Bartoloni A, Rossolini GM, Annunziato F, Vannucchi AM.Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferativeneoplasm patients receiving ruxolitinib. Am J Hematol. 2021 Jul 31. doi:10.1002/ajh.26305. Epub ahead of print. PMID: 34331712.
  4. Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, Coviello E,Romano I, Cairoli R, Lemoli R, Farina F, Venditti A, Busca A, Ladetto M, MassaiaM, Pinto A, Arcaini L, Tafuri A, Marchesi F, Fracchiolla N, Bocchia M, ArmientoD, Candoni A, Krampera M, Luppi M, Cardinali V, Galimberti S, Cattaneo C, LaBarbera EO, Mina R, Lanza F, Visani G, Musto P, Petrucci L, Zaja F, Grossi PA,Bertù L, Pagano L, Corradini P; ITA-HEMA-COV Investigators*. COVID-19 elicits animpaired antibody response against SARS-CoV-2 in patients with haematologicalmalignancies. Br J Haematol. 2021 Jul 16. doi: 10.1111/bjh.17704. Epub ahead ofprint. PMID: 34272724.
  5. Mannelli F, Gianfaldoni G, Guglielmelli P, Buccisano F, Caporale R, ChiariniM, Rossi G, Venditti A, Fazi P, Crea E, Piciocchi A, Voso MT, Vignetti M,Amadori S, Vannucchi AM. AMELIORATE: early intensification in<i>FLT3</i>-mutated acute myeloid leukemia based on peripheral blast clearance- MYNERVA-GIMEMA AML1919 trial. Future Oncol. 2021 Jul 13. doi:10.2217/fon-2021-0388. Epub ahead of print. PMID: 34254530.
  6. Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali HK, Tavares R,Maffioli M, Raanani P, Giraldo P, Griesshammer M, Guglielmelli P, Bouard C,Paley C, Tiwari R, Vannucchi AM. Comparing the safety and efficacy ofruxolitinib in patients with Dynamic International Prognostic Scoring Systemlow-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, aPhase 3b, expanded-access study. Hematol Oncol. 2021 Jul 5. doi:10.1002/hon.2898. Epub ahead of print. PMID: 34224180.
  7. Zanelli M, Loscocco GG, Sabattini E, Zizzo M, Sanguedolce F, Panico L, FanniD, Santi R, Caprera C, Rossi C, Soriano A, Cavazza A, Giunta A, Mecucci C,Vannucchi AM, Pileri SA, Ascani S. T-Cell Lymphoblastic Lymphoma Arising in theSetting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. Cancers (Basel).2021 Jun 21;13(12):3102. doi: 10.3390/cancers13123102. PMID: 34205834; PMCID:PMC8234657.
  8. Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, RoseE, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, KiladjianJJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses ofImetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Jun17:JCO2002864. doi: 10.1200/JCO.20.02864. Epub ahead of print. PMID: 34138638.
  9. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C,Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A,Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, PapadopoulosP, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E,Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, MagroMazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez AbadiaE, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B,Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, BenajibaL, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A.Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J.2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. PMID: 34135309; PMCID:PMC8208062.
  10. Gangat N, Guglielmelli P, Al-Kali A, Wolanskyj-Spinner AP, Camoriano J,Patnaik MM, Pardanani A, Hanson CA, Vannucchi AM, Tefferi A. Pregnancy inpatients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.Br J Haematol. 2021 Jun 14. doi: 10.1111/bjh.17626. Epub ahead of print. PMID:34124793.
  11. Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM,Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G,Sadek I, Tiwari R, Zor E, Al-Ali HK. Efficacy and safety of a novel dosingstrategy for ruxolitinib in the treatment of patients with myelofibrosis andanemia: the REALISE phase 2 study. Leukemia. 2021 May 20. doi:10.1038/s41375-021-01261-x. Epub ahead of print. PMID: 34017073.
  12. Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M,Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC,Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, VianelliN, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J. Direct oralanticoagulants for myeloproliferative neoplasms: results from an internationalstudy on 442 patients. Leukemia. 2021 May 19:1–5. doi:10.1038/s41375-021-01279-1. Epub ahead of print. PMID: 34012132; PMCID:PMC8132485.
  13. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT,Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, AbrahamP, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA. Fedratinib ImprovesMyelofibrosis-related Symptoms and Health-related Quality of Life in Patientswith Myelofibrosis Previously Treated with Ruxolitinib: Patient-reportedOutcomes from the Phase II JAKARTA2 Trial. Hemasphere. 2021 Apr 29;5(5):e562.doi: 10.1097/HS9.0000000000000562. PMID: 33969275; PMCID: PMC8096470.
  14. Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S,Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X,Harrison CN. Patient-reported Effects of Fedratinib, an Oral, SelectiveInhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTATrial. Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553.PMID: 33969273; PMCID: PMC8096463.
  15. Piccini M, Pilerci S, Merlini M, Grieco P, Scappini B, Bencini S, Peruzzi B,Caporale R, Signori L, Pancani F, Vannucchi AM, Gianfaldoni G. Venetoclax-BasedRegimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting:A Retrospective Single-Center Experience. J Clin Med. 2021 Apr 14;10(8):1684.doi: 10.3390/jcm10081684. PMID: 33919958; PMCID: PMC8070927.
  16. Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, MorsiaE, Sordi B, Szuber N, Hanson CA, Pardanani A, Vannucchi AM, Tefferi A. Mutationsand thrombosis in essential thrombocythemia. Blood Cancer J. 2021 Apr27;11(4):77. doi: 10.1038/s41408-021-00470-y. PMID: 33907189; PMCID: PMC8079671.
  17. Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19. PMID:
  18. Balliu M, Calabresi L, Bartalucci N, Romagnoli S, Maggi L, Manfredini R,Lulli M, Guglielmelli P, Vannucchi AM. Activated IL-6 signaling contributes tothe pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Blood Adv. 2021 Apr 27;5(8):2184-2195. doi: 10.1182/bloodadvances.2020003291.PMID: 33890979; PMCID: PMC8095134.
  19. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-KaliA, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A,Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabinein blast-phase myeloproliferative neoplasm: A multicenter series of 32consecutive cases. Am J Hematol. 2021 Jul 1;96(7):781-789. doi:10.1002/ajh.26186. Epub 2021 May 6. PMID: 33844862; PMCID: PMC8251544.
  20. Zampieri M, Allinovi M, Olivotto I, Antonioli E, Gabriele M, Argirò A,Fumagalli C, Nardi G, Di Mario C,Vannucchi AM, Perfetto F, Cappelli F.Ventricular tachyarrhythmias and sudden cardiac death in light-chainamyloidosis: a clash of cardio-toxicities? Br J Haematol. 2021May;193(4):e27-e31. doi: 10.1111/bjh.17399. Epub 2021 Apr 11. PMID: 33840100.
  21. Tanasi I, Bonifacio M, Pizzolato M, Irene Grifoni F, Sciumè M, Elena C,Benvenuti P, Mannelli F, Parente R, Schena D, Scaffidi L, Bonadonna P,Papayannidis C, Rondoni M, Criscuolo M, Vannucchi AM, Triggiani M, Martinelli G,Krampera M, Zanotti R. Familial occurrence of systemic and cutaneousmastocytosis in an adult multicentre series. Br J Haematol. 2021May;193(4):845-848. doi: 10.1111/bjh.17405. Epub 2021 Mar 22. PMID: 33754335.
  22. Loscocco GG, Antonioli E, Romano I, Vergoni F, Rotunno G, Mannelli F,Guglielmelli P, Vannucchi AM. Lenalidomide: A double-edged sword for concomitantmultiple myeloma and post-essential thrombocythemia myelofibrosis. Am J Hematol.2021 Jun 1;96(6):749-754. doi: 10.1002/ajh.26153. Epub 2021 Mar 29. PMID:33719069.
  23. Zampieri M, Cappelli F, Allinovi M, Olivotto I, Antonioli E, Tassetti L,Zocchi C, Andrei V, Di Mario C, Nozzoli C, Curciarello G, Ciciani AM, BergesioF, Vannucchi AM, Perfetto F. Incidence of light chain amyloidosis in Florencemetropolitan area, Italy: a population-based study.
  24. Rambaldi A, Iurlo A, Vannucchi AM, Martino B, Guarini A, Ruggeri M, vonBubnoff N, De Muro M, McMullin MF, Luciani S, Martinelli V, Nogai A, Rosti V,Ricco A, Bettica P, Manzoni S, Di Tollo S. Long-term safety and efficacy ofgivinostat in polycythemia vera: 4-year mean follow up of three phase 1/2studies and a compassionate use program. Blood Cancer J. 2021 Mar 6;11(3):53.doi: 10.1038/s41408-021-00445-z. PMID: 33677466; PMCID: PMC7936975.
  25. Rontauroli S, Castellano S, Guglielmelli P, Zini R, Bianchi E, Genovese E,Carretta C, Parenti S, Fantini S, Mallia S, Tavernari L, Sartini S, Mirabile M,Mannarelli C, Gesullo F, Pacilli A, Pietra D, Rumi E, Salmoiraghi S, Mora B,Villani L, Grilli A, Rosti V, Barosi G, Passamonti F, Rambaldi A, Malcovati L,Cazzola M, Bicciato S, Tagliafico E, Vannucchi AM, Manfredini R. Gene expressionprofile correlates with molecular and clinical features in patients withmyelofibrosis. Blood Adv. 2021 Mar 9;5(5):1452-1462. doi:0.1182/bloodadvances.2020003614. PMID: 33666652; PMCID: PMC7948267.
  26. Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, Gangat N. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospectivereview of vascular events and treatment strategies. Am J Hematol. 2021 Jun1;96(6):E182-E184. doi: 10.1002/ajh.26137. Epub 2021 Mar 11. PMID: 33617676.
  27. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A,Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG,Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA,Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ,Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN,Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, AbadiaEL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F,Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C,Rambaldi A, Vannucchi AM. Among classic myeloproliferative neoplasms, essentialthrombocythemia is associated with the greatest risk of venous thromboembolismduring COVID-19. Blood Cancer J. 2021 Feb 4;11(2):21. doi:
  28. Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A,Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G,Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, RumiE, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG,Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M,Finazzi MC, Tognoni G, Rambaldi A. Ropeginterferon alfa-2b versus phlebotomy inlow-risk patients with polycythaemia vera (Low-PV study): a multicentre,randomised phase 2 trial. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi:10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Erratum in: Lancet Haematol.2021 Mar;8(3):e170. PMID: 33476571.
  29. Loscocco GG, Rotunno G, Mannelli L, Mannelli F, Vergoni F, Guglielmelli P,Vannucchi AM. <i>BRAF</i>V600E mutation in the wrong place: a case ofconcomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Tumori.2021 Jan 12:300891620986621. doi: 10.1177/0300891620986621. Epub ahead of print.PMID: 33430710.
  30. Galatà G, García-Montero AC, Kristensen T, Dawoud AAZ, Muñoz-González JI,Meggendorfer M, Guglielmelli P, Hoade Y, Alvarez-Twose I, Gieger C, Strauch K,Ferrucci L, Tanaka T, Bandinelli S, Schnurr TM, Haferlach T, Broesby-Olsen S,Vestergaard H, Møller MB, Bindslev-Jensen C, Vannucchi AM, Orfao A, Radia D,Reiter A, hase AJ, Cross NCP, Tapper WJ. Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. Am JHum Genet. 2021 Feb 4;108(2):284-294. doi: 10.1016/j.ajhg.2020.12.007. Epub 2021Jan 8. PMID: 33421400; PMCID: PMC7895845.
  31. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A,Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, KiladjianJJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, MorcilloCM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS,Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, MazoEM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, CiriciBX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B,Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C,Rambaldi A. High mortality rate in COVID-19 patients with myeloproliferativeneoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7. PMID:33414483; PMCID: PMC7789078.
  32. Todisco G, Creignou M, Gallì A, Guglielmelli P, Rumi E, Roncador M, Rizzo E,Nannya Y, Pietra D, Elena C, Bono E, Molteni E, Rosti V, Catricalá S, Sarchi M,Dimitriou M, Ungerstedt J, Vannucchi AM, Hellström-Lindberg E, Ogawa S, CazzolaM, Malcovati L. Co-mutation pattern, clonal hierarchy, and clone size concur todetermine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasms. Leukemia.2021 Aug;35(8):2371-2381. doi: 10.1038/s41375-020-01106-z. Epub 2020 Dec 21.PMID: 33349666.
  33. Coltro G, Vannucchi AM. The safety of JAK kinase inhibitors for thetreatment of myelofibrosis. Expert Opin Drug Saf. 2021 Feb;20(2):139-154. doi:
  34. Zingariello M, Rosti V, Vannucchi AM, Guglielmelli P, Mazzarini M, Barosi G,Genova ML, Migliaccio AR. Shared and Distinctive Ultrastructural AbnormalitiesExpressed by Megakaryocytes in Bone Marrow and Spleen From Patients WithMyelofibrosis. Front Oncol. 2020 Nov 16;10:584541. doi:10.3389/fonc.2020.584541. PMID: 33312951; PMCID: PMC7701330.
  35. Loscocco GG, Guglielmelli P, Vannucchi AM. Impact of Mutational Profile onthe Management of Myeloproliferative Neoplasms: A Short Review of the EmergingData. Onco Targets Ther. 2020 Dec 1;13:12367-12382. doi: 10.2147/OTT.S287944.PMID: 33293830; PMCID: PMC7718985.
  36. Carobbio A, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S,Rambaldi A, Finazzi MC, Thiele J, Vannucchi AM, Tefferi A, Barbui T. Amultistate model of survival prediction and event monitoring in prefibroticmyelofibrosis. Blood Cancer J. 2020 Oct 14;10(10):100. doi:
  37. Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A,Orazzini C, Nozzoli C, Morettini A, Poggesi L, Pieralli F, Peris A, Bartoloni A,Vannucchi AM, Liotta F, Caporale R, Cosmi L, Annunziato F. Quantitative andqualitative alterations of circulating myeloid cells and plasmacytoid DC in
  38. SARS-CoV-2 infection. Immunology. 2020 Dec;161(4):345-353. doi:10.1111/imm.13254. Epub 2020 Oct 6. Erratum in: Immunology. 2021 Feb;162(2):248.PMID: 32870529; PMCID: PMC7692244.
  39. Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, Soddu S,Martino B, Palandri F, Siragusa S, Albano F, Passamonti F, Vignetti M, VannucchiAM. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMAsurvey. Leukemia. 2020 Oct;34(10):2813-2814. doi: 10.1038/s41375-020-01032-0.Epub 2020 Aug 25. PMID: 32843716; PMCID: PMC7446599.
  40. Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F,Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O,Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G,
  41. Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, AnnunziatoF, Guglielmelli P; RUXO-COVID Study Group. Compassionate use of JAK1/2 inhibitorruxolitinib for severe COVID-19: a prospective observational study. Leukemia.2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y. Epub 2020 Aug 19.PMID: 32814839; PMCID: PMC7437386.
  42. Coltro G, Rotunno G, Mannelli L, Mannarelli C, Fiaccabrino S, Romagnoli S,Bartalucci N, Ravenda E, Gelli E, Sant'Antonio E, Patnaik MM, Tefferi A,Vannucchi AM, Guglielmelli P. RAS/CBL mutations predict resistance to JAKinhibitors in myelofibrosis and are associated with poor prognostic features.Blood Adv. 2020 Aug 11;4(15):3677-3687. doi: 10.1182/bloodadvances.2020002175.PMID: 32777067; PMCID: PMC7422130.
  43. Loscocco GG, Malandrino D, Barchiesi S, Berni A, Poggesi L, Guglielmelli P,Vannucchi AM. The HScore for secondary hemophagocytic lymphohistiocytosis,calculated without a marrow biopsy, is consistently low in patients withCOVID-19. Int J Lab Hematol. 2020 Dec;42(6):e270-e273. doi: 10.1111/ijlh.13310.Epub 2020 Aug 10. PMID: 32776691.
  44. Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A,Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R,Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J,Gale RP, Mead AJ; RESUME trialists. Spliceosome mutations are common in personswith myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia. 2021Apr;35(4):1197-1202. doi: 10.1038/s41375-020-0979-6. Epub 2020 Aug 7. PMID:32770086; PMCID: PMC7610567.
  45. Gupta V, Wolleschak D, Hasselbalch H, Vannucchi AM, Koschmieder S, CervantesF, Li Y, Dong T, Wroclawska M, Bharathy S, Harrison C. Safety and efficacy ofthe combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2dose-finding study. Blood Adv. 2020 Jul 14;4(13):3063-3071. doi:10.1182/bloodadvances.2019001212. PMID: 32634234; PMCID: PMC73
  46. Palandri F, Piciocchi A, De Stefano V, Breccia M, Finazzi G, Iurlo A, FaziP, Soddu S, Martino B, Siragusa S, Albano F, Passamonti F, Vignetti M, VannucchiAM. How the coronavirus pandemic has affected the clinical management ofPhiladelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPNWP survey. Leukemia. 2020 Oct;34(10):2805-2808. doi: 10.1038/s41375-020-0953-3.Epub 2020 Jul 3. PMID: 32620840; PMCID: PMC7333222.
  47. Quattrocchi A, Maiorca C, Billi M, Tomassini S, De Marinis E, Cenfra N,Equitani F, Gentile M, Ceccherelli A, Banella C, Mecarocci S, Scerpa MC, PisanòS, Pacilli A, Di Cristofano C, Mancini M, Guglielmelli P, Vannucchi AM, NogueraN, Grignani F, Cimino G, Nervi C. Genetic lesions disrupting calreticulin3'-untranslated region in JAK2 mutation-negative polycythemia vera. Am JHematol. 2020 Jun 22. doi: 10.1002/ajh.25911. Epub ahead of print. PMID:32572989.
  48. Guglielmelli P, Vannucchi AM. Current management strategies for polycythemiavera and essential thrombocythemia. Blood Rev. 2020 Jul;42:100714. doi:10.1016/j.blre.2020.100714. Epub 2020 Jun 3. PMID: 32546373.
  49. Calvani M, Dabraio A, Bruno G, De Gregorio V, Coronnello M, Bogani C,Ciullini S, Marca G, Vignoli M, Chiarugi P, Nardi M, Vannucchi AM, Filippi L,Favre C. β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic CellsSurvival and Chemoresistance. Int J Mol Sci. 2020 Jun 12;21(12):4210. doi:10.3390/ijms21124210. PMID: 32545695; PMCID: PMC7352890.
  50. Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers (Basel). 2020 Jun 30;12(7):1746. doi: 10.3390/cancers12071746. PMID: 32629973; PMCID: PMC7407619.
  51. Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. Lysenko V, Wildner-Verhey van Wijk N, Zimmermann K, Weller MC, Bühler M, Wildschut MHE, Schürch P, Fritz C, Wagner U, Calabresi L, Psaila B, Flavell RA, Vannucchi AM, Mead AJ, Wild PJ, Dirnhofer S, Manz MG, Theocharides APA.Blood Adv. 2020 Jun 9;4(11):2477-2488. doi: 10.1182/bloodadvances.2019001364.PMID: 32502268
  52. An agenda for future research projects in polycythemia vera and essential thrombocythemia. Barbui T, Vannucchi AM, Guglielmelli P, De Stefano V, Rambaldi A.Haematologica. 2020 May 28:haematol.2019.246207. doi: 10.3324/haematol.2019.246207. Online ahead of print.PMID: 32467140No abstract available.
  53. To be, or not to be. Vannucchi AM.Blood. 2020 May 7;135(19):1617-1618. doi: 10.1182/blood.2020005363.PMID: 32379876No abstract available.
  54. Polycythemia vera: the current status of preclinical models and therapeutic targets. Bartalucci N, Guglielmelli P, Vannucchi AM.Expert Opin Ther Targets. 2020 May 18:1-14. doi: 10.1080/14728222.2020.1762176. Online ahead of print.PMID: 32366208
  55. A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Bertozzi I, Paoli C, Randi ML, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V.Blood. 2020 Apr 7:blood.2019004596. doi: 10.1182/blood.2019004596. Online ahead of print.PMID: 32266380
  56. A case of a leukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. Loscocco GG, Mannelli F, Mannelli L, Vergoni F, Gesullo F, Rotunno G, Guglielmelli P, Vannucchi AM.Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806. Online ahead of print.PMID: 32242958No abstract available.
  57. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N.Int J Mol Sci. 2020 May 30;21(11):E3900. doi: 10.3390/ijms21113900.PMID: 32486130Review.
  58. Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. Benevolo G, Elli EM, Guglielmelli P, Ricco A, Maffioli M.Leuk Lymphoma. 2020 Feb 24:1-13. doi: 10.1080/10428194.2020.1728752. Online ahead of print.PMID: 32093511
  59. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA.Am J Hematol. 2020 Jun;95(6):594-603. doi: 10.1002/ajh.25777. Epub 2020 Apr 17.PMID: 32129512
  60. The new WHO classification for essential thrombocythemia calls for revision of available evidences. Barbui T, Thiele J, Ferrari A, Vannucchi AM, Tefferi A.Blood Cancer J. 2020 Feb 25;10(2):22. doi: 10.1038/s41408-020-0290-9.PMID: 32098949Free PMC article.Review.
  61. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T.Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2.PMID: 32098944Free PMC article.
  62. Stem cell transplant for the treatment of myelofibrosis. Mannelli L, Guglielmelli P, Vannucchi AM.Expert Rev Hematol. 2020 Apr;13(4):363-374. doi: 10.1080/17474086.2020.1733406. Epub 2020 Feb 26.PMID: 32077336
  63. Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Coltro G, Mannelli F, Vergoni F, Santi R, Massi D, Siliani LM, Marzullo A, Bonifacio S, Pelo E, Pacilli A, Paoli C, Franci A, Calabresi L, Bosi A, Vannucchi AM, Guglielmelli P.Clin Exp Med. 2020 May;20(2):313-320. doi: 10.1007/s10238-020-00616-5. Epub 2020 Feb 17.PMID: 32065308
  64. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, Martino B, Pezzutto A, Carli G, De Muro M, Luciani S, McMullin MF, Cambier N, Marolleau JP, Mesa RA, Tibes R, Pancrazzi A, Gesullo F, Bettica P, Manzoni S, Di Tollo S.Leukemia. 2020 Feb 11. doi: 10.1038/s41375-020-0735-y. Online ahead of print.PMID: 32047238No abstract available.
  65. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM.Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4.PMID: 32017044
  66. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S.Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23.PMID: 31982039Clinical Trial.
  67. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM.Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16.PMID: 31945802
  68. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM.Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25721. Online ahead of print.PMID: 31925810No abstract available.
  69. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614.PMID: 31869407
  70. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.Leukemia. 2020 May;34(5):1407-1421. doi: 10.1038/s41375-019-0690-7. Epub 2019 Dec 13.PMID: 31836856
  71. Second cancers in MPN: Survival analysis from an international study. Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22.PMID: 31816122Clinical Trial.
  72. Pegasus causes inherited thrombocytopenia. Vannucchi AM.Blood. 2019 Dec 5;134(23):2000-2002. doi: 10.1182/blood.2019002181.PMID: 31805194No abstract available.
  73. Evaluation of appendicitis risk prediction models in adults with suspected appendicitis. Bhangu A; RIFT Study Group on behalf of the West Midlands Research Collaborative.Br J Surg. 2020 Jan;107(1):73-86. doi: 10.1002/bjs.11440. Epub 2019 Dec 3.PMID: 31797357Free PMC article.
  74. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.Am J Hematol. 2020 Feb;95(2):156-166. doi: 10.1002/ajh.25677. Epub 2019 Nov 29.PMID: 31721282Clinical Trial.
  75. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V; MPN-K authors.Leukemia. 2020 Apr;34(4):1208-1209. doi: 10.1038/s41375-019-0616-4. Epub 2019 Nov 7.PMID: 31700081No abstract available.
  76. Health technology assessment-based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. Gaipa G, Erba E, Danova M, Mazzini G, Venditti A, Buldini B, Specchia G, Maglia O, Kunkl A, Ciriello MM, Arpinati M, Mannelli F, Lanza F, Riccioni R, Pistotti V, Apolone G; Società Italiana di Citometria (GIC).Tumori. 2020 Feb 14:300891620904412. doi: 10.1177/0300891620904412. Online ahead of print.PMID: 32056511
  77. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Gianfaldoni G, Mannelli F, Intermesoli T, Bencini S, Giupponi D, Farina G, Cutini I, Bonetti MI, Masciulli A, Audisio E, Ferrero D, Pavoni C, Scattolin AM, Bosi A, Rambaldi A, Bassan R.Blood Adv. 2020 Jan 28;4(2):301-311. doi: 10.1182/bloodadvances.2019000406.PMID: 31978214Free PMC article.
  78. Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Bridgford JL, Lee SM, Lee CMM, Guglielmelli P, Rumi E, Pietra D, Wilcox S, Chhabra Y, Rubin AF, Cazzola M, Vannucchi AM, Brooks AJ, Call ME, Call MJ.Blood. 2020 Jan 23;135(4):287-292. doi: 10.1182/blood.2019002561.PMID: 31697803
  79. Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. Guglielmelli P, Pacilli A, Coltro G, Mannelli F, Mannelli L, Contini E, Rotunno G, Bartalucci N, Fiaccabrino S, Sordi B, Loscocco GG, Paoli C, Vannucchi AM.Am J Hematol. 2020 Jan;95(1):E23-E26. doi: 10.1002/ajh.25668. Epub 2019 Nov 12.PMID: 31659782No abstract available.
  80. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Khan S, Rodriguez V, Tefferi A, Patnaik MM.Leukemia. 2020 Jun 8. doi: 10.1038/s41375-020-0889-7. Online ahead of print.PMID: 32513965No abstract available.
  81. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Antelo G, Mangaonkar AA, Coltro G, Buradkar A, Lasho TL, Finke C, Carr R, Binder M, Gangat N, Al-Kali A, Elliott MA, King RL, Howard M, Melody ME, Hogan W, Litzow MR, Tefferi A, Fernandez-Zapico ME, Komrokji R, Patnaik MM.Br J Haematol. 2020 May;189(3):e104-e108. doi: 10.1111/bjh.16515. Epub 2020 Mar 3.PMID: 32128785No abstract available.
  82. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM.Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0752-x. Online ahead of print.PMID: 32060405No abstract available.
  83. Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Bartalucci N, Romagnoli S, Contini E, Marseglia G, Magi A, Guglielmelli P, Pelo E, Vannucchi AM.Clin Chem. 2019 Dec;65(12):1605-1608. doi: 10.1373/clinchem.2019.310805. Epub 2019 Oct 23.PMID: 31645339No abstract available.
  84. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.Am J Hematol. 2020 Jan;95(1):E1-E3. doi: 10.1002/ajh.25644. Epub 2019 Nov 1.PMID: 31588594No abstract available.
  85. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.PMID: 31515250Free PMC article.Clinical Trial.
  86. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G.Blood Cancer J. 2019 Aug 8;9(8):61. doi: 10.1038/s41408-019-0225-5.PMID: 31395856Free PMC article.
  87. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30.PMID: 31363161Free PMC article.No abstract available.
  88. A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases. Grifoni FI, Sciumè M, Pravettoni V, Ulivieri FM, Muratori S, Fracchiolla NS, Tagliaferri E, Gianelli U, Migliorini AC, Cro L, Pacilli A, Mannelli F, Baldini L.Hematol Oncol. 2019 Apr;37(2):205-211. doi: 10.1002/hon.2605. Epub 2019 Apr 4.PMID: 30849188
  89. Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A.J Blood Med. 2018 Dec 27;10:21-27. doi: 10.2147/JBM.S186786. eCollection 2019.PMID: 30643475Free PMC article.
  90. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, Pennucci V, Ruberti S, Rossi C, Rontauroli S, Enzo E, Calabresi L, Balliu M, Mannarelli C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.Sci Rep. 2019 Jul 22;9(1):10558. doi: 10.1038/s41598-019-46843-z.PMID: 31332222Free PMC article.
  91. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.Loscocco GG, Mannelli F, Guglielmelli P, Paoli C, Marone I, Cucci R, Coltro G, Sordi B, Albano F, Breccia M, De Stefano V, Finazzi G, Iurlo A, Martino B, Palandri F, Passamonti F, Siragusa S, Mannelli L, Fantoni D, Fazi P, Amadori S, Vignetti M, Barbui T, Vannucchi AM.Am J Hematol. 2019 Sep;94(9):E239-E242. doi: 10.1002/ajh.25555. Epub 2019 Jun 22.PMID: 31179561Clinical Trial.No abstract available.
  92. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.PMID: 31173472Free PMC article.
  93. Patients with Crohn's disease have longer post-operative in-hospital stay than patients with colon cancer but no difference in complications' rate. 2015 European Society of Coloproctology (ESCP) collaborating group.World J Gastrointest Surg. 2019 May 27;11(5):261-270. doi: 10.4240/wjgs.v11.i5.261.PMID: 31171957Free PMC article.
  94. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.PMID: 31142846Clinical Trial.
  95. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T.Haematologica. 2019 Dec;104(12):2391-2399. doi: 10.3324/haematol.2019.221234. Epub 2019 May 23.PMID: 31123026Free PMC article.
  96. Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P.Blood. 2019 Jun 27;133(26):2802-2808. doi: 10.1182/blood.2018879536. Epub 2019 May 10.PMID: 31076447No abstract available.
  97. NanoR: A user-friendly R package to analyze and compare nanopore sequencing data. Bolognini D, Bartalucci N, Mingrino A, Vannucchi AM, Magi A.PLoS One. 2019 May 9;14(5):e0216471. doi: 10.1371/journal.pone.0216471. eCollection 2019.PMID: 31071140Free PMC article.
  98. Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. Mannelli F, Gesullo F, Rotunno G, Pacilli A, Bencini S, Annunziato F, Zanotti R, Scaffidi L, Giona F, Santopietro M, Grifoni F, Pieri L, Guglielmelli P, Vannucchi AM.Am J Hematol. 2019 Aug;94(8):845-852. doi: 10.1002/ajh.25506. Epub 2019 May 21.PMID: 31056768
  99. Comments on pre-fibrotic myelofibrosis and how should it be managed. Barbui T, Thiele J, Gisslinger H, Orazi A, Vannucchi AM, Gianelli U, Beham-Schmid C, Tefferi A.Br J Haematol. 2019 Jul;186(2):358-360. doi: 10.1111/bjh.15840. Epub 2019 Mar 7.PMID: 30847907No abstract available.
  100. CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Dal Molin A, Bresolin S, Gaffo E, Tretti C, Boldrin E, Meyer LH, Guglielmelli P, Vannucchi AM, Te Kronnie G, Bortoluzzi S.Front Genet. 2019 Feb 13;10:88. doi: 10.3389/fgene.2019.00088. eCollection 2019.PMID: 30815012Free PMC article.
  101. Validation of the Mayo alliance prognostic system for mastocytosis. Mannelli F, Gesullo F, Rotunno G, Pacilli A, Pieri L, Guglielmelli P, Vannucchi AM.Blood Cancer J. 2019 Feb 11;9(2):18. doi: 10.1038/s41408-019-0179-7.PMID: 30741929Free PMC article.No abstract available.
  102. The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all. Vannucchi AM, Guglielmelli P.Am J Hematol. 2019 Mar;94(3):283-285. doi: 10.1002/ajh.25367. Epub 2018 Dec 18.PMID: 30499143No abstract available.
  103. Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Coltro G, Patnaik MM.Curr Oncol Rep. 2019 Nov 14;21(11):101. doi: 10.1007/s11912-019-0855-6.PMID: 31728739Review.
  104. Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Tischer A, Antelo G, Coltro G, Finke CM, Gonsalves W, Pardanani A, Ketterling R, Mangaonkar A, Gangat N, Tefferi A, Patnaik MM, Lasho TL.Leuk Res. 2019 Dec;87:106264. doi: 10.1016/j.leukres.2019.106264. Epub 2019 Oct 24.PMID: 31706195No abstract available.
  105. Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. Li M, Shah M, Binder M, Lasho T, Carr R, Mangaonkar A, Gangat N, Coltro G, Tefferi A, Dao L, Peters M, Chiu A, Patnaik MM.Am J Hematol. 2020 Feb;95(2):E31-E34. doi: 10.1002/ajh.25675. Epub 2019 Dec 4.PMID: 31705546No abstract available.
  106. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11.PMID: 31511613No abstract available.
  107. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Breccia M, Baratè C, Benevolo G, Bonifacio M, Elli EM, Guglielmelli P, Maffioli M, Malato A, Mendicino F, Palumbo GA, Pugliese N, Rossi E, Rumi E, Sant'Antonio E, Ricco A, Tiribelli M, Palandri F.Ann Hematol. 2020 Jan;99(1):65-72. doi: 10.1007/s00277-019-03847-z. Epub 2019 Dec 12.PMID: 31832751Free PMC article.
  108. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, Bonifacio M, Parisi A, Gattei V, Zamò A, Mannelli F, García Montero AC, Zanotti R.Hematol Oncol. 2019 Dec;37(5):628-633. doi: 10.1002/hon.2680. Epub 2019 Oct 21.PMID: 31523839
  109. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM.Haematologica. 2019 Dec;104(12):e551-e554. doi: 10.3324/haematol.2018.209965. Epub 2019 May 9.PMID: 31073072Free PMC article.No abstract available.
  110. Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.Am J Hematol. 2019 Sep;94(9):E231-E234. doi: 10.1002/ajh.25552. Epub 2019 Jun 14.PMID: 31173385No abstract available.
  111. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM.Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9.PMID: 30478311Free PMC article.No abstract available.
  112. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P.Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x.PMID: 30467377Free PMC article.
  113. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.PMID: 30442723Free PMC article.Clinical Trial.
  114. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y.PMID: 30420642Free PMC article.
  115. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.PMID: 30413432Free PMC article.
  116. Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. Barbui T, Finazzi G, Vannucchi AM, De Stefano V.Blood Cancer J. 2018 Nov 7;8(11):103. doi: 10.1038/s41408-018-0143-y.PMID: 30405115Free PMC article.No abstract available.
  117. Prefibrotic myelofibrosis: treatment algorithm 2018. Finazzi G, Vannucchi AM, Barbui T.Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z.PMID: 30405096Free PMC article.Review.
  118. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.PMID: 30304655Free PMC article.Clinical Trial.
  119. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.PMID: 30291232Free PMC article.No abstract available.
  120. Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al. Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.Leukemia. 2018 Dec;32(12):2727-2728. doi: 10.1038/s41375-018-0259-x. Epub 2018 Sep 28.PMID: 30267006No abstract available.
  121. Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. Rossi C, Zini R, Rontauroli S, Ruberti S, Prudente Z, Barbieri G, Bianchi E, Salati S, Genovese E, Bartalucci N, Guglielmelli P, Tagliafico E, Rosti V, Barosi G, Vannucchi AM, Manfredini R; AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) investigators.Mol Oncol. 2018 Dec;12(12):2102-2123. doi: 10.1002/1878-0261.12387. Epub 2018 Nov 16.PMID: 30259659Free PMC article.
  122. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM.Blood. 2018 Nov 8;132(19):2053-2066. doi: 10.1182/blood-2018-05-848408. Epub 2018 Sep 13.PMID: 30213875Free PMC article.
  123. Myelofibrosis Treatment Algorithm 2018. Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM.Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0.PMID: 30065290Free PMC article.Review.
  124. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28.PMID: 29955128No abstract available.
  125. The impact of stapling technique and surgeon specialism on anastomotic failure after right-sided colorectal resection: an international multicentre, prospective audit. 2015 European Society of Coloproctology Collaborating Group.Colorectal Dis. 2018 Nov;20(11):1028-1040. doi: 10.1111/codi.14308. Epub 2018 Jul 12.PMID: 29920945Clinical Trial.
  126. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C.Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3.PMID: 29880847Free PMC article.Clinical Trial.
  127. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23.PMID: 29734070Clinical Trial.No abstract available.
  128. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30.PMID: 29708808No abstract available.
  129. A case of disseminated blastic plasmocytoid dendritic cell neoplasm. Loscocco GG, Piccini M, Vergoni F, Vannucchi AM, Bosi A.Am J Hematol. 2018 Nov;93(11):1433-1434. doi: 10.1002/ajh.25109. Epub 2018 Jul 24.PMID: 29664121No abstract available.
  130. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.PMID: 29654267Free PMC article.
  131. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.PMID: 29622658Free PMC article.No abstract available.
  132. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.PMID: 29535299Free PMC article.Clinical Trial.
  133. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.PMID: 29515238Free PMC article.Review.
  134. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.PMID: 29459662Free PMC article.
  135. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A.Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y.PMID: 29426921Free PMC article.Review.
  136. The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, Lenta E, Guglielmelli P, Croce S, Cobianchi L, Jemos B, Campanelli R, Bonetti E, Di Buduo CA, Salmoiraghi S, Villani L, Massa M, Boni M, Zappatore R, Iurlo A, Rambaldi A, Vannucchi AM, Bernasconi P, Balduini A, Barosi G, Rosti V; AGIMM Investigators.Am J Hematol. 2018 May;93(5):615-622. doi: 10.1002/ajh.25047. Epub 2018 Feb 8.PMID: 29359451
  137. Polycythemia vera treatment algorithm 2018. Tefferi A, Vannucchi AM, Barbui T.Blood Cancer J. 2018 Jan 10;8(1):3. doi: 10.1038/s41408-017-0042-7.PMID: 29321547Free PMC article.Review.
  138. Essential thrombocythemia treatment algorithm 2018. Tefferi A, Vannucchi AM, Barbui T.Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8.PMID: 29321520Free PMC article.Review.
  139. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.PMID: 29275119Clinical Trial.
  140. JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM.Am J Hematol. 2018 Aug;93(4):E93-E96. doi: 10.1002/ajh.25017.PMID: 29274140Clinical Trial.No abstract available.
  141. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17.PMID: 29984424Clinical Trial.No abstract available.
  142. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.PMID: 29804268Free PMC article.Clinical Trial.
  143. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.PMID: 29396713Clinical Trial.
  144. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.PMID: 28780729Free PMC article.Clinical Trial.
  145. Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. Salati S, Prudente Z, Genovese E, Pennucci V, Rontauroli S, Bartalucci N, Mannarelli C, Ruberti S, Zini R, Rossi C, Bianchi E, Guglielmelli P, Tagliafico E, Vannucchi AM, Manfredini R.Stem Cells Dev. 2017 Dec 19. doi: 10.1089/scd.2017.0137. Online ahead of print.PMID: 29258411
  146. Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis. Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, Annunziato F, Guglielmelli P, Vannucchi AM.Oncotarget. 2017 May 22;8(57):96710-96724. doi: 10.18632/oncotarget.18073. eCollection 2017 Nov 14.PMID: 29228564Free PMC article.
  147. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.PMID: 29226763Clinical Trial.
  148. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?Vannucchi AM, Guglielmelli P.Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):480-488. doi: 10.1182/asheducation-2017.1.480.PMID: 29222296Free PMC article.Review.
  149. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.Zini R, Guglielmelli P, Pietra D, Rumi E, Rossi C, Rontauroli S, Genovese E, Fanelli T, Calabresi L, Bianchi E, Salati S, Cazzola M, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators.Blood Cancer J. 2017 Dec 8;7(12):638. doi: 10.1038/s41408-017-0010-2.PMID: 29217833Free PMC article.
  150. Polycythemia vera and essential thrombocythemia: algorithmic approach.Vannucchi AM, Guglielmelli P, Tefferi A.Curr Opin Hematol. 2018 Mar;25(2):112-119. doi: 10.1097/MOH.0000000000000402.PMID: 29194068Review.
  151. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM.Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.PMID: 29164670
  152. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.PMID: 29096334
  153. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V.J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.PMID: 28962635Free PMC article.Clinical Trial.
  154. Traffic lights for ruxolitinib.Vannucchi AM, Guglielmelli P.Blood. 2017 Aug 31;130(9):1075-1077. doi: 10.1182/blood-2017-07-795880.PMID: 28860323No abstract available.
  155. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN.Leuk Res. 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10.PMID: 28843161
  156. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21.PMID: 28827411Free PMC article.Clinical Trial.No abstract available.
  157. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Coltro G, Guglielmelli P, Vannucchi AM.Am J Hematol. 2017 Nov;92(11):1193-1197. doi: 10.1002/ajh.24882. Epub 2017 Aug 28.PMID: 28795425
  158. Genetic Risk Assessment in Myeloproliferative Neoplasms. Tefferi A, Vannucchi AM.Mayo Clin Proc. 2017 Aug;92(8):1283-1290. doi: 10.1016/j.mayocp.2017.06.002.PMID: 28778261Review.
  159. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.PMID: 28745329Free PMC article.
  160. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.Erba BG, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, Villeval JL, Vannucchi AM, Barosi G, Balduini A, Dejana E.Am J Pathol. 2017 Aug;187(8):1879-1892. doi: 10.1016/j.ajpath.2017.04.006.PMID: 28728747
  161. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G.Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. Epub 2017 Jul 29.PMID: 28699191
  162. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian JJ, Gianelli U, Silver R, Mughal TI, Barbui T.Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.PMID: 28685840
  163. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.PMID: 28602585Clinical Trial.
  164. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.PMID: 28561069
  165. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.Pacilli A, Fanelli T, Mannarelli C, Rotunno G, Pancrazzi A, Vannucchi AM, Guglielmelli P.Hematol Oncol. 2018 Feb;36(1):357-359. doi: 10.1002/hon.2424. Epub 2017 May 5.PMID: 28474777No abstract available.
  166. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2.PMID: 28465517No abstract available.
  167. Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.Guglielmelli P, Pietra D, Pane F, Pancrazzi A, Cazzola M, Vannucchi AM, Tura S, Barosi G.Leuk Res. 2017 Jul;58:63-72. doi: 10.1016/j.leukres.2017.04.006. Epub 2017 Apr 23.PMID: 28460339Review.
  168. A life-threatening ruxolitinib discontinuation syndrome.Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM.Am J Hematol. 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775. Epub 2017 Jun 1.PMID: 28457008No abstract available.
  169. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ.Ann Hematol. 2017 Jul;96(7):1113-1120. doi: 10.1007/s00277-017-2994-x. Epub 2017 Apr 30.PMID: 28456851Free PMC article.Clinical Trial.
  170. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.Rontauroli S, Norfo R, Pennucci V, Zini R, Ruberti S, Bianchi E, Salati S, Prudente Z, Rossi C, Rosti V, Guglielmelli P, Barosi G, Vannucchi A, Tagliafico E, Manfredini R.Oncotarget. 2017 Mar 28;8(13):21380-21397. doi: 10.18632/oncotarget.15226.PMID: 28423484Free PMC article.
  171. Kaposi sarcoma in a patient treated with ruxolitinib.Loscocco GG, Vannucchi M, Paoli C, Franci A, Pieri L, Annunziato F, Massi D, Vannucchi AM.Ann Oncol. 2017 Jul 1;28(7):1670-1671. doi: 10.1093/annonc/mdx188.PMID: 28419187No abstract available.
  172. Early Results of Surgical Simultaneous Therapy for Significant Carotid Artery Stenosis and Heart Disease.Irqsusi M, Vannucchi A, Beckers J, Kasseckert S, Waldhans S, Vogt S, Moosdorf RGH.Thorac Cardiovasc Surg. 2018 Apr;66(3):261-265. doi: 10.1055/s-0037-1601425. Epub 2017 Apr 5.PMID: 28380656
  173. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F.Eur J Haematol. 2017 Jul;99(1):36-41. doi: 10.1111/ejh.12887. Epub 2017 May 5.PMID: 28370510Clinical Trial.
  174. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.PMID: 28351937Clinical Trial.
  175. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.PMID: 28336242Clinical Trial.
  176. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2.PMID: 28255021Free PMC article.Review.No abstract available.
  177. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323.PMID: 28248313No abstract available.
  178. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.PMID: 28228104Free PMC article.
  179. Diagnostic impact of the 2016 revised who criteria for polycythemia vera.Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A.Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. Epub 2017 Mar 4.PMID: 28196400No abstract available.
  180. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM.Leuk Res. 2017 May;56:52-59. doi: 10.1016/j.leukres.2017.01.032. Epub 2017 Jan 31.PMID: 28193568Clinical Trial.
  181. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.Bianchi E, Ruberti S, Rontauroli S, Guglielmelli P, Salati S, Rossi C, Zini R, Tagliafico E, Vannucchi AM, Manfredini R.Int J Mol Sci. 2017 Jan 13;18(1):145. doi: 10.3390/ijms18010145.PMID: 28098757Free PMC article.
  182. Emerging treatments for classical myeloproliferative neoplasms.Vannucchi AM, Harrison CN.Blood. 2017 Feb 9;129(6):693-703. doi: 10.1182/blood-2016-10-695965. Epub 2016 Dec 27.PMID: 28028027Review.
  183. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G.Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.PMID: 27916398Clinical Trial.
  184. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25.PMID: 27885272Clinical Trial.No abstract available.
  185. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Vannucchi AM.Haematologica. 2017 Jan;102(1):18-29. doi: 10.3324/haematol.2015.129155.
  186. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, Colagrande S, Castellani A, Masciulli A, Rosti V, De Stefano V, Betti S, Finazzi G, Ferrari ML, Rumi E, Ruggeri M, Nichele I, Guglielmelli P, Fjerza R, Mannarelli C, Fanelli T, Merli L, Corbizi Fattori G, Massa M, Cimino G, Rambaldi A, Barosi G, Cazzola M, Barbui T, Vannucchi AM.Am J Hematol. 2017 Feb;92(2):187-195. doi: 10.1002/ajh.24614.PMID: 27880982Clinical Trial.
  187. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B.Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.PMID: 27858987Free PMC article.Clinical Trial.
  188. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T.Leuk Lymphoma. 2017 Jun;58(6):1481-1487. doi: 10.1080/10428194.2016.1246733. Epub 2016 Nov 10.PMID: 27830999
  189. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24.PMID: 27773929Free PMC article.Clinical Trial.
  190. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T.Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.PMID: 27740634
  191. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583.PMID: 27737508Clinical Trial.No abstract available.
  192. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Koren-Michowitz M, Lavi N, Ellis MH, Vannucchi AM, Mesa R, Harrison CN.Ann Hematol. 2017 Jan;96(1):87-92. doi: 10.1007/s00277-016-2826-4. Epub 2016 Oct 13.PMID: 27734130
  193. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.PMID: 27540137Free PMC article.
  194. Managing patients with myelofibrosis and low platelet counts. Al-Ali HK, Vannucchi AM.Ann Hematol. 2017 Apr;96(4):537-548. doi: 10.1007/s00277-016-2697-8. Epub 2016 May 21.PMID: 27209535Review.

 

 


ARS Toscana

Banner ARS 20210713

Questo sito utilizza cookie tecnici, propri e di terze parti, per il corretto funzionamento delle pagine web e per il miglioramento dei servizi.

Continuando la navigazione ne accetti il loro utilizzo. Per saperne di più o non consentirne l'utilizzo leggi Maggiori Informazioni

Continua